Taking stock of the drug industry, from the lab to the medicine chestFebruary 13, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Watch: Blockbuster drug Humira has new competition. Here's why that matters Humira has been the world's best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition. By Alex Hogan and Ed Silverman STAT+ | In another pharma shakeup, Sanofi's R&D chief takes new role at Johnson & Johnson Sanofi head of R&D John Reed is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. By Allison DeAngelis and Matthew Herper Sen. Tammy Baldwin criticizes Ascension's for-profit investment activities, requests returns and fees info Sen. Tammy Baldwin on Monday blasted Ascension for service cuts at hospitals in Wisconsin and questioned its investment activities. By Rachel Cohrs Alex Hogan/ STAT Patients still have no protection against surprise ambulance bills. And there's no solution in sight Ambulances were excluded from the federal law that banned most types of surprise medical bills, and there's no solution in sight. By Bob Herman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments